Effects of endostar thoracic hyperthermia perfusion on advanced lung cancer with malignant pleural effusion

Abstract

Objective To observe the short-term treatment effects of recombinant human endostatin (endostar) hyperthermia perfusion on advanced lung cancer with malignant pleural effusion, endostar topical safety, tolerance and care. Methods Forty cases with malignant pleural effusion in patients with advanced lung cancer, the application delivery endostar thoracic hyperthermia perfusion (single drug group), draw out the pleural effusion as much as possible, were slowly injected into hyperthermia endostar 30 mg, 2 times every week, every 60-90 min one time, treat 2 to 3 weeks until the chest water stability keeping one time every week maintenance therapy. Fifteen patients receiving both of which endostar combined etoposide ( VP-16) pleural hyperthermia infusion of local heat treatment (combination group). Every 21 days for a cycle. Recent evaluation of efficacy, quality of life and toxicity. Results Forty patients available for objective evaluation of efficacy and safety evaluation, CR 4 cases, PR 17 cases, SD 11 cases, PD 8 patients, objective response rate was 52.5%, disease control rate was 80%. Objective response rate in combination group was higher than that in single-drug group,but there was no statistical difference (P＞0.05). Improved quality of life for all patients who had 25 cases(62.5%). Drug-related toxicity was not obvious. Conclusions Pleural hyperthermia perfusion endostar administration can control the malignant pleural effusion better, reduce the clinical symptoms.Endostar and VP-16 combined with local treatment may have some synergistic effect, can improve patients quality of life, good safety, VP-16 does not increase adverse drug reactions. Key words: Recombinant human endostatin; Lung cancer; Etoposide; Pleural effusion; Hyperthermia